1TZG | L:107-213; M:107-213 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING HUMAN FAB 4E10 IN COMPLEX WITH A 13-RESIDUE PEPTIDE CONTAINING THE 4E10 EPITOPE ON GP41 |
1U6A | L:108-213 | CRYSTAL STRUCTURE OF THE BROADLY NEUTRALIZING ANTI-HIV FAB F105 |
1ZA6 | A:114-220; C:114-220; E:114-220; G:114-220 | THE STRUCTURE OF AN ANTITUMOR CH2-DOMAIN-DELETED HUMANIZED ANTIBODY |
1ZLS | L:108-210 | FAB 2G12 + MAN4 |
1ZLU | K:108-212; L:108-212 | FAB 2G12 + MAN5 |
1ZLV | K:108-212; L:108-212 | FAB 2G12 + MAN7 |
1ZLW | K:108-212; L:108-210 | FAB 2G12 + MAN8 |
2AGJ | L:108-215 | CRYSTAL STRUCTURE OF A GLYCOSYLATED FAB FROM AN IGM CRYOGLOBULIN WITH PROPERTIES OF A NATURAL PROTEOLYTIC ANTIBODY |
2AJ3 | A:108-213; C:108-213; E:108-213 | CRYSTAL STRUCTURE OF A CROSS-REACTIVE HIV-1 NEUTRALIZING CD4-BINDING SITE ANTIBODY FAB M18 |
2BC4 | A:97-200; B:94-193; C:97-206; D:94-199 | CRYSTAL STRUCTURE OF HLA-DM |
2BNU | A:116-204 | STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES |
2CDG | A:116-193 | STRUCTURE AND BINDING KINETICS OF THREE DIFFERENT HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE-SPECIFIC T CELL RECEPTORS (TCR 5B) |
2CMR | L:107-207 | CRYSTAL STRUCTURE OF THE HIV-1 NEUTRALIZING ANTIBODY D5 FAB BOUND TO THE GP41 INNER-CORE MIMETIC 5-HELIX |
2D4D | A: | THE CRYSTAL STRUCTURE OF HUMAN BETA2-MICROGLOBULIN, L39W W60F W95F MUTANT |
2EYR | A:118-205; B:120-247 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2EYS | A:118-205; B:120-247 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2EYT | A:118-205; B:120-247; C:118-205; D:120-247 | A STRUCTURAL BASIS FOR SELECTION AND CROSS-SPECIES REACTIVITY OF THE SEMI-INVARIANT NKT CELL RECEPTOR IN CD1D/GLYCOLIPID RECOGNITION |
2FJF | A:108-211; C:108-211; E:108-211; G:108-211; J:108-211; L:108-211; M:108-211; O:108-211; Q:108-211; S:108-211; U:108-211; W:108-211 | STRUCTURE OF THE G6 FAB, A PHAGE DERIVED VEGF BINDING FAB |
2FJG | A:108-211; L:108-211 | STRUCTURE OF THE G6 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF |
2FJH | A:107-211; L:107-214 | STRUCTURE OF THE B20-4 FAB, A PHAGE DERIVED FAB FRAGMENT, IN COMPLEX WITH VEGF |
2FSE | A:82-181; C:82-180 | CRYSTALLOGRAPHIC STRUCTURE OF A RHEUMATOID ARTHRITIS MHC SUSCEPTIBILITY ALLELE, HLA-DR1 (DRB1*0101), COMPLEXED WITH THE IMMUNODOMINANT DETERMINANT OF HUMAN TYPE II COLLAGEN |
2H9G | A:108-211; L:108-211 | CRYSTAL STRUCTURE OF PHAGE DERIVED FAB BDF1 WITH HUMAN DEATH RECEPTOR 5 (DR5) |
2HFF | A:107-213; L:107-210 | CRYSTAL STRUCTURE OF CB2 FAB |
2HFG | L:107-212 | CRYSTAL STRUCTURE OF HBR3 BOUND TO CB3S-FAB |
2IAL | A:110-198; B:113-240; C:110-198; D:113-240 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2IAM | C:110-198; D:113-240 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2IAN | D:110-198; E:113-240; I:110-198; J:113-240; N:110-198; O:113-240; S:110-198; T:113-240 | STRUCTURAL BASIS FOR RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED TCR |
2J6E | A:236-339; A:340-445; B:238-339; B:340-446; M:109-211 | CRYSTAL STRUCTURE OF AN AUTOIMMUNE COMPLEX BETWEEN A HUMAN IGM RHEUMATOID FACTOR AND IGG1 FC REVEALS A NOVEL FC EPITOPE AND EVIDENCE FOR AFFINITY MATURATION |
2JB5 | L:113-214 | FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-1 |
2JB6 | A:113-214; L:113-214 | FAB FRAGMENT IN COMPLEX WITH SMALL MOLECULE HAPTEN, CRYSTAL FORM-2 |
2NW2 | A:118-206 | CRYSTAL STRUCTURE OF ELS4 TCR AT 1.4A |
2NYY | C:112-216 | CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN TYPE A COMPLEXED WITH MONOCLONAL ANTIBODY CR1 |
2OLD | A:113-217; B:113-217 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(2)21 CRYSTAL FORM |
2OMB | A:113-217; B:113-217; C:113-217; D:113-217 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P3(1)21 CRYSTAL FORM |
2OMN | A:113-217; B:113-217 | BENCE JONES KWR PROTEIN- IMMUNOGLOBULIN LIGHT CHAIN DIMER, P4(3)2(1)2 CRYSTAL FORM |
2PYF | A:116-205; B:114-241 | CRYSTAL STRUCTURES OF HIGH AFFINITY HUMAN T-CELL RECEPTORS BOUND TO PMHC REVEALNATIVE DIAGONAL BINDING GEOMETRY UNBOUND TCR CLONE 5-1 |
2QQK | L:108-211 | NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB |
2QQL | L:107-214 | NEUROPILIN-2 A1A2B1B2 DOMAINS IN COMPLEX WITH A SEMAPHORIN-BLOCKING FAB |
2QQN | L:108-214 | NEUROPILIN-1 B1 DOMAIN IN COMPLEX WITH A VEGF-BLOCKING FAB |
2R56 | L:108-211; M:108-211 | CRYSTAL STRUCTURE OF A RECOMBINANT IGE FAB FRAGMENT IN COMPLEX WITH BOVINE BETA-LACTOGLOBULIN ALLERGEN |
2VLM | D:113-201 | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN |
2VXQ | L:108-213 | CRYSTAL STRUCTURE OF THE MAJOR GRASS POLLEN ALLERGEN PHL P 2 IN COMPLEX WITH ITS SPECIFIC IGE-FAB |
2VXS | L:109-210; M:109-212; N:109-210; O:109-212 | STRUCTURE OF IL-17A IN COMPLEX WITH A POTENT, FULLY HUMAN NEUTRALISING ANTIBODY |
2VXV | L:108-213 | CRYSTAL STRUCTURE OF HUMAN IGG ABT-325 FAB FRAGMENT |
2WAH | A:238-339; A:340-444; B:237-339; B:340-445 | CRYSTAL STRUCTURE OF AN IGG1 FC GLYCOFORM (MAN9GLCNAC2) |
2WBJ | B:93-188; C:114-200; F:93-190; G:114-202 | TCR COMPLEX |
2WUB | L:108-214; Q:108-214 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP |
2WUC | L:108-214 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE |
2X89 | D:; E:; F:; G: | STRUCTURE OF THE BETA2_MICROGLOBULIN INVOLVED IN AMYLOIDOGENESIS |
2XA8 | L:112-218 | CRYSTAL STRUCTURE OF THE FAB DOMAIN OF OMALIZUMAB AT 2.41A |
2XKU | A: | PRION-LIKE CONVERSION DURING AMYLOID FORMATION AT ATOMIC RESOLUTION |
2XNA | A:112-200 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN HUMAN T CELL RECEPTOR AND STAPHYLOCOCCAL ENTEROTOXIN |
2XPG | B: | CRYSTAL STRUCTURE OF A MHC CLASS I-PEPTIDE COMPLEX |
2XQB | L:108-209 | CRYSTAL STRUCTURE OF ANTI-IL-15 ANTIBODY IN COMPLEX WITH HUMAN IL-15 |
2XWT | B:108-213 | CRYSTAL STRUCTURE OF THE TSH RECEPTOR IN COMPLEX WITH A BLOCKING TYPE TSHR AUTOANTIBODY |
2XZA | L:110-216 | CRYSTAL STRUCTURE OF RECOMBINANT A.17 ANTIBODY FAB FRAGMENT |
2XZC | L:110-216 | CRYSTAL STRUCTURE OF PHOSPHONATE-MODIFIED RECOMBINANT A.17 ANTIBODY FAB FRAGMENT |
2YK1 | L:108-205 | STRUCTURE OF HUMAN ANTI-NICOTINE FAB FRAGMENT IN COMPLEX WITH NICOTINE |
2YKL | L:108-208 | STRUCTURE OF HUMAN ANTI-NICOTINE FAB FRAGMENT IN COMPLEX WITH NICOTINE-11-YL-METHYL-(4-ETHYLAMINO-4-OXO)-BUTANOATE |
3AGV | A:241-339; A:340-443; B:237-339; B:340-444 | CRYSTAL STRUCTURE OF A HUMAN IGG-APTAMER COMPLEX |
3BDY | L:108-213 | DUAL SPECIFIC BH1 FAB IN COMPLEX WITH VEGF |
3BE1 | L:108-212 | DUAL SPECIFIC BH1 FAB IN COMPLEX WITH THE EXTRACELLULAR DOMAIN OF HER2/ERBB-2 |
3BN9 | C:108-210; E:108-211 | CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2 |
3BQU | A:108-211 | CRYSTAL STRUCTURE OF THE 2F5 FAB'-3H6 FAB COMPLEX |
3BZF | B:; D: | THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E |
3C08 | L:107-211 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF MATUZUMAB/EMD72000 (FAB72000) |
3C2S | A:236-339; A:340-445 | STRUCTURAL CHARACTERIZATION OF A HUMAN FC FRAGMENT ENGINEERED FOR LACK OF EFFECTOR FUNCTIONS |
3C5J | B:93-190 | CRYSTAL STRUCTURE OF HLA DR52C |
3D85 | A:108-213 | CRYSTAL STRUCTURE OF IL-23 IN COMPLEX WITH NEUTRALIZING FAB |
3DGG | A:111-217; C:111-215 | CRYSTAL STRUCTURE OF FABOX108 |
3DIF | A:108-213; C:108-214 | CRYSTAL STRUCTURE OF FABOX117 |
3DX9 | A:126-215; B:130-257; C:126-215; D:130-257 | CRYSTAL STRUCTURE OF THE DM1 TCR AT 2.75A |
3EO9 | L:108-213 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF EFALIZUMAB |
3EOA | A:108-214; L:108-214 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF EFALIZUMAB IN COMPLEX WITH LFA-1 I DOMAIN, FORM I |
3EYO | A:109-213; C:109-214 | CRYSTAL STRUCTURE OF ANTI-HUMAN CYTOMEGALOVIRUS ANTIBODY 8F9 |
3EYQ | C:109-212 | CRYSTAL STRUCTURE OF MJ5 FAB, A GERMLINE ANTIBODY VARIANT OF ANTI-HUMAN CYTOMEGALOVIRUS ANTIBODY 8F9 |
3F12 | A:110-212; C:110-214 | GERMLINE V-GENES SCULPT THE BINDING SITE OF A FAMILY OF ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS |
3FJT | A:236-339; A:340-444; B:236-339; B:340-444 | CRYSTAL STRUCTURE OF A HUMAN FC FRAGMENT ENGINEERED FOR EXTENDED SERUM HALF-LIFE |
3FZU | D:108-213; L:108-213 | IGG1 FAB CHARACTERIZED BY H/D EXCHANGE |
3G6A | A:109-210; L:109-210 | CRYSTAL STRUCTURE OF ANTI-IL-13 ANTIBODY CNTO607 |
3G6J | E:107-214; G:107-214 | C3B IN COMPLEX WITH A C3B SPECIFIC FAB |
3GBM | L:108-213; M:112-211 | CRYSTAL STRUCTURE OF FAB CR6261 IN COMPLEX WITH A H5N1 INFLUENZA VIRUS HEMAGGLUTININ. |
3GIZ | L:108-211 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF ANTI-CD20 ANTIBODY OFATUMUMAB |
3GJE | A:111-212; L:111-212 | RATIONAL DEVELOPMENT OF HIGH-AFFINITY T-CELL RECEPTOR-LIKE ANTIBODIES |
3GKW | L:108-207 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF NIMOTUZUMAB. AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY |
3GRW | L:108-214 | FGFR3 IN COMPLEX WITH A FAB |
3GSN | A:112-200; B:117-244; H:182-274 | CRYSTAL STRUCTURE OF THE PUBLIC RA14 TCR IN COMPLEX WITH THE HCMV DOMINANT NLV/HLA-A2 EPITOPE |
3GSO | A:182-274 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV PEPTIDE |
3GSQ | A:182-274 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5S PEPTIDE VARIANT |
3GSR | A:182-274 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5V PEPTIDE VARIANT |
3GSU | A:182-275 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5T PEPTIDE VARIANT |
3GSV | A:182-275 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-M5Q PEPTIDE VARIANT |
3GSW | A:182-274 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8A PEPTIDE VARIANT |
3GSX | A:182-274 | CRYSTAL STRUCTURE OF THE BINARY COMPLEX BETWEEN HLA-A2 AND HCMV NLV-T8V PEPTIDE VARIANT |
3H0T | A:112-216 | HEPCIDIN-FAB COMPLEX |
3H42 | L:113-214 | CRYSTAL STRUCTURE OF PCSK9 IN COMPLEX WITH FAB FROM LDLR COMPETITIVE ANTIBODY |
3H9Y | A:336-438; A:439-544; B:335-438; B:439-544; E:336-438; E:439-544 | CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS |
3H9Z | A:336-438; A:439-544; B:336-438; B:439-544; C:336-438; C:439-544; D:336-438; D:439-544 | CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS |
3HA0 | A:336-438; A:439-544; B:336-438; B:439-544; C:336-438; C:439-544; D:336-438; D:439-544; E:336-438; E:439-544; F:336-438; F:439-544 | CRYSTAL STRUCTURE OF THE IGE-FC3-4 DOMAINS |
3HC0 | B:108-213; L:108-212 | BHA10 IGG1 WILD-TYPE FAB - ANTIBODY DIRECTED AT HUMAN LTBR |
3HC3 | L:108-213 | BHA10 IGG1 FAB DOUBLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR |
3HC4 | L:108-213 | BHA10 IGG1 FAB QUADRUPLE MUTANT VARIANT - ANTIBODY DIRECTED AT HUMAN LTBR |
3HI1 | A:108-214; L:108-214 | STRUCTURE OF HIV-1 GP120 (CORE WITH V3) IN COMPLEX WITH CD4-BINDING-SITE ANTIBODY F105 |
3HI5 | L:107-211 | CRYSTAL STRUCTURE OF FAB FRAGMENT OF AL-57 |
3HI6 | L:107-211; Y:107-210 | CRYSTAL STRUCTURE OF INTERMEDIATE AFFINITY I DOMAIN OF INTEGRIN LFA-1 WITH THE FAB FRAGMENT OF ITS ANTIBODY AL-57 |
3HMW | L:107-214 | CRYSTAL STRUCTURE OF USTEKINUMAB FAB |
3HMX | L:107-214 | CRYSTAL STRUCTURE OF USTEKINUMAB FAB/IL-12 COMPLEX |
3HUJ | E:118-206; F:119-247; G:118-206; H:119-247 | CRYSTAL STRUCTURE OF HUMAN CD1D-ALPHA-GALACTOSYLCERAMIDE IN COMPLEX WITH SEMI-INVARIANT NKT CELL RECEPTOR |
3IDX | L:108-213 | CRYSTAL STRUCTURE OF HIV-GP120 CORE IN COMPLEX WITH CD4-BINDING SITE ANTIBODY B13, SPACE GROUP C222 |
3INU | L:108-211; N:108-211 | CRYSTAL STRUCTURE OF AN UNBOUND KZ52 NEUTRALIZING ANTI-EBOLAVIRUS ANTIBODY. |
3JWD | L:108-214; O:108-213 | STRUCTURE OF HIV-1 GP120 WITH GP41-INTERACTIVE REGION: LAYERED ARCHITECTURE AND BASIS OF CONFORMATIONAL MOBILITY |
3K2U | L:108-214 | CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40 |
3KR3 | L:109-214 | CRYSTAL STRUCTURE OF IGF-II ANTIBODY COMPLEX |
3KYM | A:108-213; C:108-213; E:108-213; G:108-213; I:108-213; K:108-212; M:108-208; O:108-213 | CRYSTAL STRUCTURE OF LI33 IGG2 DI-FAB |
3L5X | L:108-214 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND H2L6 FAB |
3L7F | A:108-213; D:108-213; L:108-213 | STRUCTURE OF IL-13 ANTIBODY H2L6, A HUMANIZED VARIANT OF C836 |
3LMJ | L:113-215 | STRUCTURE OF HUMAN ANTI HIV 21C FAB |
3LRS | B:108-209; D:108-209; F:108-209; L:108-209 | STRUCTURE OF PG16, AN ANTIBODY WITH BROAD AND POTENT NEUTRALIZATION OF HIV-1 |
3LZF | L:108-211 | CRYSTAL STRUCTURE OF FAB 2D1 IN COMPLEX WITH THE 1918 INFLUENZA VIRUS HEMAGGLUTININ |
3M1B | A:177-267; C:177-267; E:177-267; G:177-267 | CRYSTAL STRUCTURE OF HUMAN FCRN WITH A DIMERIC PEPTIDE INHIBITOR |
3M8O | L:113-219 | HUMAN IGA1 FAB FRAGMENT |
3MFF | A:122-210; B:116-243; C:122-210; D:116-243 | 1F1E8HU TCR |
3MLR | L:112-213 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH A NY5 V3 PEPTIDE |
3MLS | L:112-213; M:112-213; N:112-213; O:112-213 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 MAB 2557 FAB IN COMPLEX WITH A HIV-1 GP120 V3 MIMOTOPE |
3MLT | A:112-213; D:112-213; G:112-213; L:112-213 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH A UG1033 V3 PEPTIDE |
3MLU | L:113-213 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH A ZAM18 V3 PEPTIDE |
3MLV | L:113-213; M:113-213 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 2557 IN COMPLEX WITH AN NOF V3 PEPTIDE |
3MLW | L:108-209; M:108-209 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 1006-15D IN COMPLEX WITH AN MN V3 PEPTIDE |
3MLX | L:109-209; M:109-209 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 3074 IN COMPLEX WITH AN MN V3 PEPTIDE |
3MLY | L:108-211; M:108-211 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 3074 IN COMPLEX WITH A UR29 V3 PEPTIDE |
3MLZ | L:108-211 | CRYSTAL STRUCTURE OF ANTI-HIV-1 V3 FAB 3074 IN COMPLEX WITH A VI191 V3 PEPTIDE |
3MUG | A:108-212; C:108-212; E:108-212; G:108-212; I:108-212; K:108-213 | CRYSTAL STRUCTURE OF HUMAN FAB PG16, A BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
3MUH | L:108-212 | CRYSTAL STRUCTURE OF PG9 LIGHT CHAIN |
3MXW | L:108-212 | CRYSTAL STRUCTURE SONIC HEDGEHOG BOUND TO THE 5E1 FAB FRAGMENT |
3N9G | L:112-220 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THE HUMAN NEUTRALIZING ANTI-WEST NILE VIRUS MAB CR4354 |
3NA9 | L:108-214 | CRYSTAL STRUCTURE OF FAB15 |
3NAA | L:108-214 | CRYSTAL STRUCTURE OF FAB15 MUT5 |
3NAB | L:108-214 | CRYSTAL STRUCTURE OF FAB15 MUT6 |
3NAC | L:108-214 | CRYSTAL STRUCTURE OF FAB15 MUT7 |
3NCJ | L:108-214 | CRYSTAL STRUCTURE OF FAB15 MUT8 |
3NFP | B:107-212; L:107-212 | CRYSTAL STRUCTURE OF THE FAB FRAGMENT OF THERAPEUTIC ANTIBODY DACLIZUMAB IN COMPLEX WITH IL-2RA (CD25) ECTODOMAIN |
3NFS | L:107-212 | CRYSTAL STRUCTURE THE FAB FRAGMENT OF THERAPEUTIC ANTIBODY DACLIZUMAB |
3NPS | C:108-212 | CRYSTAL STRUCTURE OF MEMBRANE-TYPE SERINE PROTEASE 1 (MT-SP1) IN COMPLEX WITH THE FAB INHIBITOR S4 |
3NZH | L:108-214 | CRYSTAL STRUCTURE OF ANTI-EMMPRIN ANTIBODY 5F6 FAB |
3O4L | D:112-201 | GENETIC AND STRUCTURAL BASIS FOR SELECTION OF A UBIQUITOUS T CELL RECEPTOR DEPLOYED IN EPSTEIN-BARR VIRUS |
3O6F | C:111-196; G:111-196 | CRYSTAL STRUCTURE OF A HUMAN AUTOIMMUNE TCR MS2-3C8 BOUND TO MHC CLASS II SELF-LIGAND MBP/HLA-DR4 |
3OAY | K:108-213; L:108-213 | A NON-SELF SUGAR MIMIC OF THE HIV GLYCAN SHIELD SHOWS ENHANCED ANTIGENICITY |
3OAZ | K:108-213; L:108-213 | A NON-SELF SUGAR MIMIC OF THE HIV GLYCAN SHIELD SHOWS ENHANCED ANTIGENICITY |
3OB0 | K:108-213; L:108-212 | A NON-SELF SUGAR MIMIC OF THE HIV GLYCAN SHIELD SHOWS ENHANCED ANTIGENICITY |
3OF6 | A:120-245; B:120-247; C:120-247 | HUMAN PRE-T CELL RECEPTOR CRYSTAL STRUCTURE |
3P0V | L:108-212; M:108-212 | ANTI-EGFR/HER3 FAB DL11 ALONE |
3P0Y | L:108-213 | ANTI-EGFR/HER3 FAB DL11 IN COMPLEX WITH DOMAIN III OF EGFR EXTRACELLULAR REGION |
3PGF | L:108-214 | CRYSTAL STRUCTURE OF MALTOSE BOUND MBP WITH A CONFORMATIONALLY SPECIFIC SYNTHETIC ANTIGEN BINDER (SAB) |
3PL6 | B:95-191; C:114-192 | STRUCTURE OF AUTOIMMUNE TCR HY.1B11 IN COMPLEX WITH HLA-DQ1 AND MBP 85-99 |
3PWP | E:118-246 | THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND HUD PEPTIDE |
3Q6F | A:108-211; C:108-211; E:108-211; G:108-211; I:108-211; K:108-211 | CRYSTAL STRUCTURE OF FAB OF HUMAN MAB 2909 SPECIFIC FOR QUATERNARY NEUTRALIZING EPITOPE OF HIV-1 GP120 |
3QDG | D:111-199; E:118-245 | THE COMPLEX BETWEEN TCR DMF5 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(26-35)(A27L) PEPTIDE |
3QDJ | D:111-199; E:118-245 | THE COMPLEX BETWEEN TCR DMF5 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(27-35) NONAMERIC PEPTIDE |
3QDM | D:110-196; E:116-243 | THE COMPLEX BETWEEN TCR DMF4 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(26-35)(A27L) DECAMERIC PEPTIDE |
3QEG | L:108-212 | CRYSTAL STRUCTURE OF HUMAN N12-I2 FAB, AN ADCC AND NEUTRALIZING ANTI-HIV-1 ENV ANTIBODY |
3QEH | B:107-210; D:107-210; F:107-210; H:107-210 | CRYSTAL STRUCTURE OF HUMAN N12-I15, AN ADCC AND NON-NEUTRALIZING ANTI-HIV-1 ENV ANTIBODY |
3QEQ | D:110-195 | THE COMPLEX BETWEEN TCR DMF4 AND HUMAN CLASS I MHC HLA-A2 WITH THE BOUND MART-1(27-35) NONAMERIC PEPTIDE |
3QEU | A:111-201; B:118-241; D:111-201; E:118-245 | THE CRYSTAL STRUCTURE OF TCR DMF5 |
3QFJ | E:118-246 | THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2 WITH THE MODIFIED TAX (Y5F) PEPTIDE |
3QH3 | A:112-194; B:117-245; C:112-194; D:117-245 | THE CRYSTAL STRUCTURE OF TCR A6 |
3QHF | L:108-213 | CRYSTAL STRUCTURE OF FAB DEL2D1, A DELETION VARIANT OF ANTI-INFLUENZA ANTIBODY 2D1 |
3QHZ | L:108-215; M:108-212 | CRYSTAL STRUCTURE OF HUMAN ANTI-INFLUENZA FAB 2D1 |
3QIB | C:112-201 | CRYSTAL STRUCTURE OF THE 2B4 TCR IN COMPLEX WITH MCC/I-EK |
3QNX | A:113-219 | ORTHORHOMBIC FORM OF HUMAN IGA1 FAB FRAGMENT, SHARING SAME FV AS IGG |
3QNY | A:113-219; C:113-219 | MONOCLINIC FORM OF HUMAN IGA1 FAB FRAGMENT, SHARING SAME FV AS IGG |
3QO1 | A:113-219 | MONOCLINIC FORM OF IGG1 FAB FRAGMENT (APO FORM) SHARING SAME FV AS IGA |
3QOS | | [entry was replaced by entry 5I1D without any SCOP domain information] |
3QOT | | [entry was replaced by entry 5I18 without any SCOP domain information] |
3QPQ | C:108-215; E:108-215; I:108-215; L:108-215 | CRYSTAL STRUCTURE OF ANTI-TLR3 ANTIBODY C1068 FAB |
3QPX | L:107-213 | CRYSTAL STRUCTURE OF FAB C2507 |
3QQ9 | C:112-217; L:112-217 | CRYSTAL STRUCTURE OF FAB FRAGMENT OF ANTI-HUMAN RSV (RESPIRATORY SYNCYTIAL VIRUS) F PROTEIN MAB 101F |
3QRG | L:112-217 | CRYSTAL STRUCTURE OF ANTIRSVF FAB B21M |
3R1G | L:108-214 | STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE-BINDING ANTIBODY |
3REV | A:118-205; B:116-242 | CRYSTAL STRUCTURE OF HUMAN ALLOREACTIVE TCR NB20 |
3RPI | B:97-202; L:97-202 | CRYSTAL STRUCTURE OF FAB FROM 3BNC60, HIGHLY POTENT ANTI-HIV ANTIBODY |
3S7G | A:236-339; A:340-443; B:236-339; B:340-442; C:237-339; C:340-444; D:238-339; D:340-444 | AGLYCOSYLATED HUMAN IGG1 FC FRAGMENT |
3SDX | E:115-203; G:115-203 | CRYSTAL STRUCTURE OF HUMAN AUTOREACTIVE-VALPHA24 NKT TCR IN COMPLEX WITH CD1D-BETA-GALACTOSYLCERAMIDE |
3SDY | L:108-214 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY CR8020 BOUND TO THE INFLUENZA A H3 HEMAGGLUTININ |
3SE8 | L:108-213 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC03 IN COMPLEX WITH HIV-1 GP120 |
3SE9 | L:108-214 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-PG04 IN COMPLEX WITH HIV-1 GP120 |
3SKJ | L:108-214; M:108-214 | STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF AN AGONISTIC ANTI-HUMAN EPHA2 MONOCLONAL ANTIBODY |
3SKN | A:125-214; B:127-255; C:125-214; D:127-255; E:125-214; F:127-255; G:125-214; H:127-255 | CRYSTAL STRUCTURE OF THE RL42 TCR UNLIGANDED |
3SO3 | B:108-213 | STRUCTURES OF FAB-PROTEASE COMPLEXES REVEAL A HIGHLY SPECIFIC NON-CANONICAL MECHANISM OF INHIBITION. |
3T2N | L:109-209; M:109-210 | HUMAN HEPSIN PROTEASE IN COMPLEX WITH THE FAB FRAGMENT OF AN INHIBITORY ANTIBODY |
3TCL | B:108-213; L:108-213 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING ANTIBODY CH04 |
3THM | L:112-214 | CRYSTAL STRUCTURE OF FAS RECEPTOR EXTRACELLULAR DOMAIN IN COMPLEX WITH FAB EP6B_B01 |
3TJE | L:112-213 | CRYSTAL STRUCTURE OF FAS RECEPTOR EXTRACELLULAR DOMAIN IN COMPLEX WITH FAB E09 |
3TNM | B:108-208; L:108-208 | CRYSTAL STRUCTURE OF A32 FAB, AN ADCC MEDIATING ANTI-HIV-1 ANTIBODY |
3TNN | B:109-210; D:109-210; F:109-210; L:109-210 | CRYSTAL STRUCTURE OF N5-I5 FAB, AN ADCC MEDIATING AND NON-NEUTRALIZING CD4I ANTI-HIV- 1 ANTIBODY. |
3TO4 | C:118-207; D:122-247 | STRUCTURE OF MOUSE VALPHA14VBETA2-MOUSECD1D-ALPHA-GALACTOSYLCERAMIDE |
3TV3 | L:108-211 | CRYSTAL STRUCTURE OF BROAD AND POTENT HIV-1 NEUTRALIZING ANTIBODY PGT128 IN COMPLEX WITH MAN9 |
3TWC | L:108-214 | CRYSTAL STRUCTURE OF BROAD AND POTENT HIV-1 NEUTRALIZING ANTIBODY PGT127 IN COMPLEX WITH MAN9 |
3TZV | A:115-200; G:115-203 | CRYSTAL STRUCTURE OF AN INKT TCR IN COMPLEX WITH CD1D-LYSOPHOSPHATIDYLCHOLINE |
3U2S | B:108-208; L:108-208 | CRYSTAL STRUCTURE OF PG9 FAB IN COMPLEX WITH V1V2 REGION FROM HIV-1 STRAIN ZM109 |
3U30 | B:108-211; E:108-211 | CRYSTAL STRUCTURE OF A LINEAR-SPECIFIC UBIQUITIN FAB BOUND TO LINEAR UBIQUITIN |
3U46 | B:108-213; L:108-213 | CH04H/CH02L P212121 |
3U4B | L:108-213 | CH04H/CH02L FAB P4 |
3U4E | B:108-209; L:108-210 | CRYSTAL STRUCTURE OF PG9 FAB IN COMPLEX WITH V1V2 REGION FROM HIV-1 STRAIN CAP45 |
3UTP | D:113-200; E:118-246; K:113-202; L:118-246 | 1E6 TCR SPECIFIC FOR HLA-A*0201-ALWGPDPAAA |
3V7M | A:236-339; A:340-444 | CRYSTAL STRUCTURE OF MONOCLONAL HUMAN ANTI-RHESUS D FC IGG1 T125(YB2/0) IN THE PRESENCE OF ZN2+ |
3VWJ | C:118-206 | TERNARY CRYSTAL STRUCTURE OF THE HUMAN NKT TCR-CD1D-C20:2 COMPLEX |
3VWK | C:118-204; D:119-246 | TERNARY CRYSTAL STRUCTURE OF THE HUMAN NKT TCR-CD1D-4'DEOXY-ALPHA-GALACTOSYLCERAMIDE COMPLEX |
3VXQ | A:114-204; D:114-204 | H27-14 TCR SPECIFIC FOR HLA-A24-NEF134-10 |
3VXT | A:112-200; C:112-200 | T36-5 TCR SPECIFIC FOR HLA-A24-NEF134-10 |
3W9D | B:108-212; D:108-213 | STRUCTURE OF HUMAN MONOCLONAL ANTIBODY E317 FAB |
3W9E | B:108-211 | STRUCTURE OF HUMAN MONOCLONAL ANTIBODY E317 FAB COMPLEX WITH HSV-2 GD |
3WD5 | L:107-213 | CRYSTAL STRUCTURE OF TNFALPHA IN COMPLEX WITH ADALIMUMAB FAB FRAGMENT |
3ZL4 | L:111-216 | ANTIBODY STRUCTURAL ORGANIZATION: ROLE OF KAPPA - LAMBDA CHAIN CONSTANT DOMAIN SWITCH IN CATALYTIC FUNCTIONALITY |
4AEN | B:93-190 | HLA-DR1 WITH COVALENTLY LINKED CLIP106-120 IN REVERSED ORIENTATION |
4AL8 | L:108-213 | STRUCTURE OF DENGUE VIRUS DIII IN COMPLEX WITH FAB 2H12 |
4AM0 | B:108-212; D:108-212; F:108-212; L:108-212 | STRUCTURE OF DENGUE VIRUS STRAIN 4 DIII IN COMPLEX WITH FAB 2H12 |
4B7I | A:237-339; A:340-444; B:238-339; B:340-444 | CRYSTAL STRUCTURE OF HUMAN IGG FC BEARING HYBRID-TYPE GLYCANS |
4D9L | L:109-209; M:109-210; N:109-210; O:109-210 | FAB STRUCTURE OF ANTI-HIV-1 GP120 V2 MAB 697 |
4D9Q | D:108-213; L:108-213 | INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D |
4D9R | D:108-213; L:108-214 | INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D |
4DKF | L:107-212; M:107-208 | CRYSTAL STRUCTURE OF HUMAN INTERLEUKIN-34 BOUND TO FAB2 |
4DN3 | L:109-214 | CRYSTAL STRUCTURE OF ANTI-MCP-1 ANTIBODY CNTO888 |
4DQO | L:108-210 | CRYSTAL STRUCTURE OF PG16 FAB IN COMPLEX WITH V1V2 REGION FROM HIV-1 STRAIN ZM109 |
4DTG | L:112-219 | HEMOSTATIC EFFECT OF A MONOCLONAL ANTIBODY MAB 2021 BLOCKING THE INTERACTION BETWEEN FXA AND TFPI IN A RABBIT HEMOPHILIA MODEL |
4DZB | A:111-199; B:118-245 | MUCOSAL-ASSOCIATED INVARIANT T CELL RECEPTOR, VALPHA7.2JALPHA33-VBETA2 |
4E41 | D:111-199; E:111-238; I:111-198; J:111-238 | STRUCTURAL BASIS FOR THE RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED T CELL RECEPTOR G4 |
4E42 | A:111-198; B:111-238; C:111-198; D:111-238 | STRUCTURAL BASIS FOR THE RECOGNITION OF MUTANT SELF BY A TUMOR-SPECIFIC, MHC CLASS II-RESTRICTED T CELL RECEPTOR G4 |
4EDW | L:108-214 | NERVE GROWTH FACTOR IN COMPLEX WITH FAB FROM HUMANIZED VERSION OF MOUSE MAB 911 (TANEZUMAB) |
4EN3 | A:114-201 | CRYSTAL STRUCTURE OF A HUMAN VALPHA24(-) NKT TCR IN COMPLEX WITH CD1D/ALPHA-GALACTOSYLCERAMIDE |
4EOW | L:112-212 | CRYSTAL STRUCTURE OF A DISEASE-ASSOCIATED ANTI-HUMAN GM-CSF AUTOANTIBODY MB007 |
4ERS | L:107-214 | A MOLECULAR BASIS FOR NEGATIVE REGULATION OF THE GLUCAGON RECEPTOR |
4EVN | B:113-215; D:113-215; F:113-215; H:113-215; J:113-215; L:113-215; N:113-215; P:113-215 | CRYSTAL STRUCTURE OF FAB CR6261 (SOMATIC HEAVY CHAIN WITH GERMLINE-REVERTED LIGHT CHAIN) |
4F57 | L:109-209 | FAB STRUCTURE OF A NEUTRALIZING ANTIBODY L1 FROM AN EARLY SUBTYPE A HIV-1 INFECTED PATIENT |
4F58 | L:109-209; M:109-209; N:109-209; O:109-209 | FAB STRUCTURE OF A NEUTRALIZING ANTIBODY L3 FROM AN EARLY SUBTYPE A HIV-1 INFECTED PATIENT |
4FNL | L:107-213; M:107-213 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY C05 |
4FP8 | L:107-213; M:107-213; N:107-213; O:107-213 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY C05 BOUND TO H3 INFLUENZA HEMAGGLUTININ, HA1 SUBUNIT |
4FQ2 | L:109-212 | CRYSTAL STRUCTURE OF 10-1074 FAB |
4FQH | B:108-209; L:108-209 | CRYSTAL STRUCTURE OF FAB CR9114 |
4FQI | L:108-208 | CRYSTAL STRUCTURE OF FAB CR9114 IN COMPLEX WITH A H5N1 INFLUENZA VIRUS HEMAGGLUTININ |
4FQJ | L:108-211 | INFLUENZA B/FLORIDA/4/2006 HEMAGGLUTININ FAB CR8071 COMPLEX |
4FQL | L:108-214 | INFLUENZA B HA ANTIBODY (FAB) CR8033 |
4FQQ | A:109-210; C:109-209; E:109-209; L:109-212 | CRYSTAL STRUCTURE OF GERMLINE ANTIBODY PGT121-GL FAB |
4FQX | B:93-190; C:97-200; D:94-193 | CRYSTAL STRUCTURE OF HLA-DM BOUND TO HLA-DR1 |
4FZ8 | L:108-211 | CRYSTAL STRUCTURE OF C11 FAB, AN ADCC MEDIATING ANTI-HIV-1 ANTIBODY. |
4FZE | L:108-210 | CRYSTAL STRUCTURE OF N26_I1 FAB, AN ADCC MEDIATING ANTI-HIV-1 ANTIBODY. |
4G3Y | L:108-214 | CRYSTAL STRUCTURE OF TNF-ALPHA IN COMPLEX WITH INFLIXIMAB FAB FRAGMENT |
4G7V | L:108-211 | CRYSTAL STRUCTURE OF VOLTAGE SENSING DOMAIN OF CI-VSP WITH FRAGMENT ANTIBODY (R217E, 2.5 A) |
4G7Y | L:108-211 | CRYSTAL STRUCTURE OF VOLTAGE SENSING DOMAIN OF CI-VSP WITH FRAGMENT ANTIBODY (R217E, 2.8 A) |
4G8E | A:128-217; B:135-262 | CRYSTAL STRUCTURE OF CLONE18 TCR |
4G8F | A:129-205; B:128-256 | CRYSTAL STRUCTURE OF CLONE42 TCR |
4GKZ | A:116-201; B:115-242 | HA1.7, A MHC CLASS II RESTRICTED TCR SPECIFIC FOR HAEMAGGLUTININ |
4GRL | A:82-180; B:95-191; C:114-192 | CRYSTAL STRUCTURE OF A AUTOIMMUNE TCR-MHC COMPLEX |
4GRM | A:118-194; B:118-246; C:118-193; D:118-245 | THE CRYSTAL STRUCTURE OF THE HIGH AFFINITY TCR A6 |
4GSD | L:109-211 | H5.3 FAB STRUCTURE |
4GT7 | A:334-438; A:439-545; B:333-438; B:439-545; C:332-438; C:439-545; D:333-438; D:439-545 | AN ENGINEERED DISULFIDE BOND REVERSIBLY TRAPS THE IGE-FC3-4 IN A CLOSED, NON-RECEPTOR BINDING CONFORMATION |
4GW4 | B:97-199; L:97-198 | CRYSTAL STRUCTURE OF 3BNC60 FAB WITH P61A MUTATION |
4GXV | L:108-209; M:108-209 | CRYSTAL STRUCTURE OF ANTI-INFLUENZA VIRUS ANTIBODY 1F1 |
4H25 | B:93-190; E:93-190 | TCR INTERACTION WITH PEPTIDE MIMICS OF NICKEL OFFERS STRUCTURE INSIGHTS TO NICKEL CONTACT ALLERGY |
4H26 | B:93-190; E:93-190 | TCR INTERACTION WITH PEPTIDE MIMICS OF NICKEL OFFERS STRUCTURE INSIGHT TO NICKEL CONTACT ALLERGY |
4H8W | L:109-209 | CRYSTAL STRUCTURE OF NON-NEUTRALIZING AND ADCC-POTENT ANTIBODY N5-I5 IN COMPLEX WITH HIV-1 CLADE A/E GP120 AND SCD4. |
4HCR | L:112-218; N:112-218 | CRYSTAL STRUCTURE OF HUMAN MADCAM-1 D1D2 COMPLEXED WITH FAB PF-547659 |
4HF5 | L:108-208 | CRYSTAL STRUCTURE OF FAB 8F8 IN COMPLEX A H2N2 INFLUENZA VIRUS HEMAGGLUTININ |
4HFU | L:107-212 | CRYSTAL STRUCTURE OF FAB 8M2 IN COMPLEX WITH A H2N2 INFLUENZA VIRUS HEMAGGLUTININ |
4HFW | A:107-211; L:107-212 | ANTI ROTAVIRUS ANTIBODY |
4HH9 | A:108-214; C:108-214 | ANTI-HUMAN CYTOMEGALOVIRUS (HCMV) FAB KE5 |
4HJG | A:108-214 | MEDITOPE-ENABLED TRASTUZUMAB |
4HK0 | B:110-210; D:110-210 | UCA FAB (UNBOUND) FROM CH65-CH67 LINEAGE |
4HK3 | N:110-210 | I2 FAB (UNBOUND) FROM CH65-CH67 LINEAGE |
4HKX | B:110-211 | INFLUENZA HEMAGGLUTININ IN COMPLEX WITH CH67 FAB |
4HKZ | A:108-213 | TRASTUZUMAB FAB COMPLEXED WITH PROTEIN L AND PROTEIN A FRAGMENTS |
4HQQ | L:108-208 | CRYSTAL STRUCTURE OF RV144-ELICITED ANTIBODY CH58 |
4HWE | L:105-210 | CRYSTAL STRUCTURE OF ECTODOMAIN 3 OF THE IL-13 RECEPTOR ALPHA1 IN COMPLEX WITH A HUMAN NEUTRALIZING MONOCLONAL ANTIBODY FRAGMENT |
4I2X | A:108-214; C:108-214 | CRYSTAL STRUCTURE OF SIGNAL REGULATORY PROTEIN GAMMA (SIRP-GAMMA) IN COMPLEX WITH FABOX117 |
4I3R | L:107-214 | CRYSTAL STRUCTURE OF THE OUTER DOMAIN OF HIV-1 GP120 IN COMPLEX WITH VRC-PG04 SPACE GROUP P3221 |
4I3S | L:108-214 | CRYSTAL STRUCTURE OF THE OUTER DOMAIN OF HIV-1 GP120 IN COMPLEX WITH VRC-PG04 SPACE GROUP P21 |
4I77 | L:108-214 | LEBRIKIZUMAB FAB BOUND TO IL-13 |
4IIQ | A:111-201; B:117-244 | CRYSTAL STRUCTURE OF A HUMAN MAIT TCR IN COMPLEX WITH BOVINE MR1 |
4IOI | A:108-214 | MEDITOPE-ENABLED TRASTUZUMAB IN COMPLEX WITH CQFDLSTRRLKC |
4IRJ | C:116-204 | STRUCTURE OF THE MOUSE CD1D-4CLPHC-ALPHA-GALCER-INKT TCR COMPLEX |
4J12 | A:236-339; A:340-444 | MONOMERIC FC |
4J4P | D:131-233; L:131-233 | THE COMPLEX OF HUMAN IGE-FC WITH TWO BOUND FAB FRAGMENTS |
4J6R | L:108-214 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC23 IN COMPLEX WITH HIV-1 GP120 |
4JAM | B:108-209; L:108-209 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODY CH103 |
4JAN | B:106-207; L:106-207 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY CH103 IN COMPLEX WITH HIV-1 GP120 |
4JB9 | L:103-209 | CRYSTAL STRUCTURE OF ANTIBODY VRC06 IN COMPLEX WITH HIV-1 GP120 CORE |
4JDV | B:104-209; L:104-209 | CRYSTAL STRUCTURE OF GERM-LINE PRECURSOR OF NIH45-46 FAB |
4JFH | D:111-200; E:117-244 | HIGH AFFINITY ALPHA24-BETA17 T CELL RECEPTOR FOR A2 HLA-MELANOMA PEPTIDE COMPLEX |
4JFX | A:108-214; L:108-214 | STRUCTURE OF PHOSPHOTYROSINE (PTYR) SCAFFOLD BOUND TO PTYR PEPTIDE |
4JFY | A:108-211; L:108-213 | APO STRUCTURE OF PHOSPHOTYROSINE (PYAB) SCAFFOLD |
4JFZ | L:108-214 | STRUCTURE OF PHOSPHOSERINE (PSAB) SCAFFOLD BOUND TO PSER PEPTIDE |
4JG0 | L:108-214 | STRUCTURE OF PHOSPHOSERINE/THREONINE (PSTAB) SCAFFOLD BOUND TO PSER PEPTIDE |
4JG1 | L:108-214 | STRUCTURE OF PHOSPHOSERINE/THREONINE (PSTAB) SCAFFOLD BOUND TO PTHR PEPTIDE |
4JHA | L:108-211 | CRYSTAL STRUCTURE OF RSV-NEUTRALIZING HUMAN ANTIBODY D25 |
4JM2 | B:107-214; C:110-212 | CRYSTAL STRUCTURE OF PGT 135 FAB IN COMPLEX WITH GP120 CORE PROTEIN FROM HIV-1 STRAIN JR-FL BOUND TO CD4 AND 17B FAB |
4JM4 | L:108-214 | CRYSTAL STRUCTURE OF PGT 135 FAB |
4JPI | B:110-214; L:110-213 | CRYSTAL STRUCTURE OF A PUTATIVE VRC01 GERMLINE PRECURSOR FAB |
4JPK | L:110-214 | CRYSTAL STRUCTURE OF THE GERMLINE-TARGETING HIV-1 GP120 ENGINEERED OUTER DOMAIN EOD-GT6 IN COMPLEX WITH A PUTATIVE VRC01 GERMLINE PRECURSOR FAB |
4JPV | L:108-212 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY 3BNC117 IN COMPLEX WITH HIV-1 GP120 |
4JPW | L:108-212 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY 12A21 IN COMPLEX WITH HIV-1 STRAIN 93TH057 GP120 MUTANT |
4JY5 | L:109-209 | CRYSTAL STRUCTURE OF HUMAN FAB PGT122, A BROADLY REACTIVE AND POTENT HIV-1 NEUTRALIZING ANTIBODY |
4K71 | B:177-268; E:177-268 | CRYSTAL STRUCTURE OF A HIGH AFFINITY HUMAN SERUM ALBUMIN VARIANT BOUND TO THE NEONATAL FC RECEPTOR |
4K7P | X:108-214 | GENERATION AND CHARACTERIZATION OF A UNIQUE REAGENT THAT RECOGNIZES A PANEL OF RECOMBINANT HUMAN MONOCLONAL ANTIBODY THERAPEUTICS IN THE PRESENCE OF ENDOGENOUS HUMAN IGG |
4KMT | L:108-214 | CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY 5-51/O12 |
4KQ3 | L:107-211 | CRYSTAL STRUCTURE OF ANTI-IL-17A ANTIBODY CNTO3186 |
4KVN | L:107-212 | CRYSTAL STRUCTURE OF FAB 39.29 IN COMPLEX WITH INFLUENZA HEMAGGLUTININ A/PERTH/16/2009 (H3N2) |
4KY1 | L:108-213 | HUMANIZED HP1/2 FAB |
4L4T | D:111-200; G:111-199 | STRUCTURE OF HUMAN MAIT TCR IN COMPLEX WITH HUMAN MR1-6-FP |
4L4V | D:111-200; G:111-198 | STRUCTURE OF HUMAN MAIT TCR IN COMPLEX WITH HUMAN MR1-RL-6-ME-7-OH |
4L8S | A:111-200 | CRYSTAL STRUCTURE OF A HUMAN VALPHA7.2/VBETA13.3 MAIT TCR IN COMPLEX WITH BOVINE MR1 |
4LCW | D:111-200; G:111-198 | THE STRUCTURE OF HUMAN MAIT TCR IN COMPLEX WITH MR1-K43A-RL-6-ME-7OH |
4LFH | G:126-238 | CRYSTAL STRUCTURE OF 9C2 TCR |
4LHU | G:126-236 | CRYSTAL STRUCTURE OF 9C2 TCR BOUND TO CD1D |
4LKC | A:109-214 | AN ANTIBODY AGAINST THE C-TERMINAL DOMAIN OF PCSK9 LOWERS LDL CHOLESTEROL LEVELS IN VIVO |
4LMQ | I:108-214; L:108-214 | DEVELOPMENT AND PRECLINICAL CHARACTERIZATION OF A HUMANIZED ANTIBODY TARGETING CXCL12 |
4LSP | L:108-212 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-CH31 IN COMPLEX WITH HIV-1 CLADE A/E GP120 93TH057 |
4LSQ | L:108-213 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-CH31 IN COMPLEX WITH HIV-1 CLADE A/E GP120 93TH057 WITH LOOP D AND LOOP V5 FROM CLADE A STRAIN 3415_V1_C1 |
4LSU | L:108-211 | CRYSTAL STRUCTURE OF BROADLY AND POTENTLY NEUTRALIZING ANTIBODY VRC-PG20 IN COMPLEX WITH HIV-1 CLADE A/E 93TH057 GP120 |
4M6M | L:113-216 | CRYSTAL STRUCTURE OF ANTI-IL-23 ANTIBODY CNTO1959 AT PH 9.5 |
4M6O | L:108-214 | CRYSTAL STRUCTURE OF ANTI-NGF ANTIBODY CNTO7309 |
4MAY | A:82-180; B:95-191; C:114-192 | CRYSTAL STRUCTURE OF AN IMMUNE COMPLEX |
4MNG | A:184-278; C:184-278 | STRUCTURE OF THE DP10.7 TCR WITH CD1D-SULFATIDE |
4MWF | B:108-213; L:108-213 | STRUCTURE OF HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 CORE BOUND TO BROADLY NEUTRALIZING ANTIBODY AR3C |
4NDM | A:119-246; B:122-212 | STRUCTURE OF THE AB18.1 TCR |
4NM4 | L:108-213; M:108-213 | CRYSTAL STRUCTURE OF BROADLY NEUTRALIZING ANTIBODY CR8043 |
4NRZ | B:108-212; L:108-213 | CRYSTAL STRUCTURE OF HIV-1 NEUTRALIZING ANTIBODY M66.6 |
4NZR | L:108-214 | CRYSTAL STRUCTURE OF THE ANTIBODY-BINDING REGION OF PROTEIN M (PROTEIN M TD) IN COMPLEX WITH ANTI-HIV ANTIBODY PGT135 FAB |
4NZT | L:108-212 | CRYSTAL STRUCTURE OF THE ANTIBODY-BINDING REGION OF PROTEIN M (PROTEIN M TD) IN COMPLEX WITH ANTI-INFLEUNZA HEMAGGLUTININ ANTIBODY CR9114 FAB |
4NZU | L:108-211 | CRYSTAL STRUCTURE OF THE PRIMARY MONOCLONAL ANTIBODY 13PL FAB' FROM A MULTIPLE MYELOMA PATIENT |
4OAW | C:108-214 | FAB STRUCTURE OF ANTI-HIV GP120 V2 MAB 2158 |
4OCS | L:108-209 | CRYSTAL STRUCTURE OF HUMAN FAB CAP256-VRC26.10, A POTENT V1V2-DIRECTED HIV-1 NEUTRALIZING ANTIBODY |
4OD1 | L:108-208 | CRYSTAL STRUCTURE OF HUMAN FAB CAP256-VRC26.03, A POTENT V1V2-DIRECTED HIV-1 NEUTRALIZING ANTIBODY |
4OD3 | L:108-209 | CRYSTAL STRUCTURE OF HUMAN FAB CAP256-VRC26.07, A POTENT V1V2-DIRECTED HIV-1 NEUTRALIZING ANTIBODY |
4PS4 | L:107-213 | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN IL-13 AND M1295 FAB |